Parkinson's disease is a common neurodegenerative disorder characterized by tremors, dystonia, and bradykinesia. 1 It occurs in a sporadic or a familial form. We have recently demonstrated a locus for early onset FPD on chromosome 4q21-q23, and identified a mutation in the alpha synuclein gene responsible for the phenotype. 2 The mutation, a single amino acid substitution (Ala53Thr), was found in one Italian and three Greek kindreds with FPD. A second mutation, an Ala30Pro change, was subsequently described in a German kindred. 3 Alpha synuclein is an abundant presynaptic protein of unknown function. This protein and its homologues have been isolated from fish, rats, birds and humans. 4, 5 It appears to reside in nerve terminals and the only function known to date is an involvement in the song learning process in the zebra finch. 6 The human protein was initially identified because a peptide fragment of alpha synuclein was found in plaques of patients with Alzheimer's disease, suggesting that mutations in this gene might be responsible for some cases of Alzheimer's disease. 7 However a search for mutations in the alpha synuclein gene in families with early onset Alzheimer's disease yielded no mutations.
Lewy bodies (LB) were first described in 1912 by Freiderich H Lewy who observed them in brains from patients with PD. 9 In Parkinson's disease LB are usually present in the brainstem, basal forebrain and the autonomic ganglia, with the highest concentrations in the substantia nigra and the locus coeruleus. Although first found associated with PD, Lewy bodies have been described in other neurodegenerative disorders as well, including diffuse Lewy body disease (DLBD), thought to be the second most frequent cause of dementia after AD. 10 In contrast to PD, DLBD is characterized by a progressive dementia along with the parkinsonian motor disorder. While LB are very sparse in cerebral cortex of patients with PD, they are frequently found in DLBD.
Although the exact composition of the LB is not known, a number of proteins are thought to take part in its formation. [11] [12] [13] The most widely studies of these proteins is ubiquitin, immunostaining for which is commonly used to identify the LB.
14 Epitopes for the neurofilament chain proteins M, L, and H have also been identified in LB. 15 Ubiquitin-reactive Lewy bodies are known to exist in different forms, including round bodies of 2-40 m diameter with a distinct core and halo, swollen neuronal processes packed with protein deposit referred to as Lewy neurites, 16 and degenerating neural processes containing a number of LB. While ubiquitin seems to be present in virtually all LB, it may be a passive participant in the pathological process underlying their production. In other words, ubiquitin may be attracted to filamentous protein aggregates in the cell and mount a futile attempt to target them for destruction by the proteasome.
The recent discovery of a missense mutation in the alpha synuclein gene in some cases of FPD, 2 led us to the hypothesis that the mutation destabilized the structure of the protein making it susceptible to self-aggregation. In order to evaluate the role of alpha synuclein in the formation of LB in sporadic PD, we developed an antibody (SYNC) against an oligopeptide comprising the 12 C-terminal amino acids of the alpha synuclein molecule. 8 Alpha synuclein is a 140-amino acid protein, characterized by imperfect amino acid repeats. The consensus of the core of the amino acid repeat is the 6-mer Lys-Thr-Lys-Gln-Gly-Val. This core sequence and the juxtaposition of the repeats is reminiscent of a similar sequence structure in apolipoprotein E. The antibody used in this study was designed to recognize the C-terminus of the protein-thereby avoiding any overlap with the repetitive motif. The SYNC antibody was shown to specifically identify a band on Western blots from brain but not from liver. The size of the immunoreactive band was approximately 19 kD in size. This size is bigger than that predicted for the alpha synuclein molecule (14.4 kD), but it is consistent with previously published observations 4 that a 19-kD species reacts with antibodies directed against the Cterminus of the protein.
Materials and methods

Production of antibody and Western blot analysis
Polyclonal antibodies were raised against the oligopeptide SEEGYQDYEPEA corresponding to amino acids 129-140 of human alpha-synuclein (genbank ID L08850). The oligopeptide was coupled to Keyhole Limpet Hemocyanin (KLH) via an added amino-terminal cysteine residue. Antibody production was performed by injecting the coupled peptide into rabbits using the Poly Quik protocol of Zymed Laboratories (S San Francisco, CA, USA). Western blots were performed using brain and liver tissue protein extracts from Clontech (Palo Alto, CA, USA), as follows: proteins were extracted from whole-tissue by homogenization at 40°C under standard conditions in the presence of protease inhibitors (0.1 M Tris-HCl pH 7.5, 15% (v/v) glycerol, 0.2 mM EDTA, 1.0 mM DTT, 10 g ml −1 leupeptin and 1.0 mM PMSF). The samples were electrophoresed in the presence of beta-mercapto-ethanol (5%) and SDS (2%) on a 10-20% gradient acrylamide gel in SDS/Tris/Glycine buffer. Gels were run at 200 V per 50-25 mA for 30 min. Gels were soaked in 1× (transfer buffer = 10 mM CAPS (3-[Cyclohexylamino]-1-propane-sulfonic acid) pH 11 and 20% methanol for 15 min prior to elecrophoretic transfer (40 min/room temperature/50 V (170-100 mA). The transfer was made to Immobilon-P (PVDF). Transfer was checked by a brief staining in Coomassie-Blue R-250 (1 min) followed by destaining. For immuno-detection, blots were blocked in 0.1-0.2% Casein/0.1-0.2% Tween 20/ phosphate-buffered saline overnight. Primary Ab (SynC) was added at 1 : 1000 dilution of unpurified anti-serum or pre-immune serum. Ab binding was for 1-2 h at room temperature followed by 20 min of washing (3-4 changes) in PBS/0.1-0.2% Tween 20. The secondary Ab was horse-radish peroxidase donkey antirabbit IgG (Amersham, Arlington Heights, IL, USA) and incubated for 1 h at room temperature at 1 : 10 000 dilution. After a second 20-min wash in PBS/0.1% Tween 20, chemiluminescent detection of the secondary Ab was carried out with the ìECLî reagent from Amersham. Light production was detected on NEN AR autoradiography film (New England Nuclear, Boston, MA, USA). Exposure times ranged from 10-90 s.
Sequence analysis
The oligonucleotide primers used to amplify the coding exons of the alpha synuclein gene were: exon3 (syna8) acttggagggtttctcatg (syna23) ttgttatcctaacccatcac; exon 4 (syna3) gctaatcagcaatttaaggctag (syna13) gatatgttcttagatgctcag; exon 5 (syna14) atggctagtggaagtggaatg (syna15) ccccacagtagtatcttgc; exon 6 (syna16) ccacatccctatatgtaag (syna17) gagaaatgtgacaatgacagg; exon 7 (syna18) ggggtttgatttttctaat (syna22) catgtattcacttcagtgaaagg. Sequence analysis was performed using standard ABI fluorescent technology. Immunohistochemistry Twelve-micron thick sections were cut, placed on microscope slides, deparaffinized with xylene, rehydrated with graded ethanol solutions, and treated with 0.6% protease E (Sigma, St Louis, MO, USA) for 30 min. Ubiquitin was stained with a mouse monoclonal antibody (Zymed Laboratories, S San Francisco, CA, USA) at the dilution provided by the manufacturer. Synuclein was stained using the rabbit polyclonal antiserum described in the text at a dilution of 1 : 500.
Clinical sample
All primary and secondary antibodies were diluted in BSA diluent (PBS with 1% bovine serum albumin and 0.6% Triton X-100). Double immunolabeling was performed as follows with 3 × 5 min washes in PBS between steps: to reduce nonspecific staining the sections were placed in BSA diluent for 30 min each. The sections were incubated with the primary antisera overnight at 4°C, and then incubated for 1 h with the appropriate 1 : 1000 dilution of Cy3-or 1 : 100 dilution of FITC-conjugated donkey anti-IgG antiserum (F[ab′]2 IgG-fragment, affinity purified to minimize crossreactivities with IgGs other than the primary antibody (Jackson ImmunoResearch, West Grove, PA, USA). Photomicrographs were made using an Axiphot fluor- , red) antibodies respectively. The two color image (c) shows ubiquitin in the core of this particle, both proteins in the middle (orange color), and synuclein in the periphery. Another double-stained LB is shown in frame (d). In this case, synuclein was stained green and ubiquitin red. Both proteins are found in the core of the LB, but tendrils of synuclein make up the periphery. This particle appears still to be growing. The LBs shown in (e) and (f) were stained with immunoperoxidase for synuclein and ubiquitin, respectively. The LB in (e) is in the cell body of a pigmented neuron. The granules seen contain neuromelanin. The size bars correspond to 10 m.
escence microscope (Zeiss, Germany). Double color images were generated using a double pass fluorescent filter allowing detection of both FITC-green and Cy3-red. To reduce nonspecific staining when immunoperoxidase was used, the sections were placed in 3% hydrogen peroxide for 30 min before they were immersed in BSA diluent. Following the overnight incubation in primary antiserum, biotin-conjugated secondary antibodies (Vectastain ABC Elite Kit, Vector Laboratories, Burlingame, CA, USA) were applied to the sections for 1 h at final dilutions of 1 : 500. Then the sections were incubated in the avidin-biotin-peroxidase complex (1 : 250) for 1 h, transferred to Trisbuffered saline, and the peroxidase developed with DAB (DAB solution : 40 mg% DAB, 0.016 ml H 2 O 2 in 0.1 M Tris-HCl, pH 8.0, made freshly and used for 7-10 min). The color images were scanned with a Sprint Scan 35 (Polaroid) and processed using Adobe Photoshop software. As mentioned in the text, replacing the primary antibodies with preimmune serum yielded no staining, and preincubating the working dilution of the anti-synuclein antiserum with 100 g ml −1 of synuclein peptide blocked staining completely.
Results
We used the SYNC antibody to stain sections from the brain of a 76-year-old male who suffered from a sporadic form of PD. The pathology report accompanying the sample we studied confirmed the clinical diagnosis and indicated that the patient had LB disease. Genotyping DNA from this patient did not reveal the Ala53Thr mutation in the alpha synuclein gene (Figure 1 ). Further sequence analysis of all coding exons of the alpha synuclein gene revealed no mutations.
When we examined hematoxylin/eosin stained sections of the patient's substantia nigra (SN), we saw extensive neuronal loss and numerous Lewy bodies. As expected, these intracellular inclusions were ubiquitin positive. We were also able to stain LB with our SYNC antibody, and in double staining experiments to show that LB contained both ubiquitin and synuclein. No staining was found when the SYNC antibody was preincubated with the peptide used to raise it, or with preimmune serum (data not shown). The double-stained LB typically had a relatively faint central core with a bright double stained halo, surrounded by a rim of SYNC (Figure 2 ). When they were stained for synuclein or ubiquitin alone, LB frequently had a lamellar appearance. The particles observed ranged in size from a few micrometers to more than 20 micrometers in diameter, and were found in neuronal perikarya and swollen neurites. SYNC-positive fragments of degenerating neurites were even more common than LB and appeared to be the signature of the pathological process in the brain studied (Figure 3 ). The brain of an agematched, asymptomatic control individual looked very different than the PD brain. There was no evident neuronal loss in the substantia nigra. Only small scattered ubiquitin-positive bodies were present in the zona compacta. These are commonly seen in brains from elderly individuals with no overt motor problems. 17 The only structures visualized when the synuclein antibody was used for immunostaining were fine neuronal processes (Figure 4) . Axonal boutons were most intensely stained. Thus, there seems to be good correlation between synuclein deposition and the pathology of PD with Lewy bodies. Examination of the three additional brains from patients with sporadic PD revealed similar SYNC immunostaining in Lewy bodies and swollen dendritic processes. Furthermore, the substantia nigra and amygdala of a patient with diffuse Lewy body disease (DLBD) were packed with SYNC positive Lewy bodies and engorged neural processes ( Figure 4) .
We next asked whether synuclein-positive aggregates were present in the brains of patients who had suffered from brain illnesses other than PD (Figure 4) . We began by examining the brain of a women who had died of Alzheimer's disease. The neuronal cytoplasmic inclusion characteristic of this disorder is the neurofibrillary tangle. When tangles are stained by means of silver impregnation, they look like thick, black bands of parallel fibers that fill the cell body. These fibers are Figure 4 Synuclein staining in a normal brain and brains of patients who had illnesses other than Parkinson's disease. A normal substantia nigra (a) has fine scattered synuclein-positive neurites among its pigmented neurons. The substantia nigra of a patient with diffuse Lewy body disease (DLBD) (b), has many pigmented neurons with one or more Lewy bodies in their perikarya. In addition there are many stained Lewy neurites and engorged processes. Synuclein-positive swollen processes are even more prominent in the amygdala of the same patient. There the Lewy bodies tend to be smaller than in the substantia nigra, and they are more amorphous in structure (c). In the hippocampus of a patient who had Alzheimer's disease, many engorged neurites are synuclein-positive (d) and Lewy body-like round inclusions are found in some neurons in the substantia nigra of the same patient (e and f). In Pick's disease the characteristic Pick bodies in cortical neurons (arrows point at some) are strongly positive using silver impregnation (g) and immunostained for Tau (h) but the same inclusions are not stained with synuclein (i). The brains were stained with immunoperoxidase as described. Scale bars represent 10 m in a, b, c, d, e, f, and 30 m in g-i.
immunoreactive for paired helical filaments and tau, and can be seen in axons and dendrites many cell diameters from the neuronal cell body. Indeed, a dense meshwork of 'neuropil threads' is commonly observed, 18, 19 and this meshwork appeared to be synuclein-positive in layers 5 and 6 of the hippocampus of the brain we studied (Figure 4 d-f ). These layers undergo pseudolamellar necrosis following anoxic episodes, and given the presence of severe arteriosclerotic changes in the first brain we examined, we could not be sure whether the staining we saw in the hippocampus reflected AD or ischemic alterations. For this reason, we studied additional brains from patients with multiinfarct dementia and 'pure' Alzheimer's disease. We saw no specific staining in the brains with infarcts, but again saw synuclein-positive neuritic tangles in layers 5 and 6 of the brain from the patient with Alzheimer's disease. On the other hand, synuclein-stained tangles in neuronal perikarya were rare, but we did see synuclein in intraneuronal aggregates in pigmented neurons in the lateral portion of the substantia nigra. Some of these had the lamellar appearance of Lewy bodies; others were rather amorphous looking. Whether this is a common feature Alzheimer's disease, or peculiar to the patient we studied remains to be seen.
Along with tangles, plaques are another hallmark of Alzheimer's disease, and may ultimately occupy one third to one half of the cerebral cortex. These usually have a central core of amyloid protein surrounded by masses of neuritic processes, astrocytes, and microglia. Individual plaques may coalesce to form aggregates 1 mm across. Plaques were not stained by the anti-synuclein antibody. It should be noted that this antibody is directed against the C-terminus of synuclein which is not present in the fragment of the protein originally isolated from Alzheimer's plaques. If it is true that plaques are rich in the NAC35 fragment of alpha synuclein, they are not rich in the full length protein.
Next we studied Pick's disease, a rare form of late onset, slowly progressive cerebral cortical atrophy, especially affecting the frontal and temporal cortices. There one sees neuronal loss, gliosis, and swollen, pale, pear-shaped Pick cells, but not plaques or tangles. In addition, some neurons contain argyrophilic Pick bodies. These are fairly well defined, round, inclusions which can sometimes nearly fill the cytoplasm. They seem to be comprised of masses of tubules and filaments.
We could detect readily Pick bodies on archival sections of brains from patients who had died of Pick's disease stained by silver impregnation or immunocytochemistry with anti-tau antibodies. These bodies were easy to see in sections cut from the same block as the original ones and counterstained with Geimsa stain, but they appeared to contain no alpha-synuclein.
Discussion
The presence of the alpha synuclein in the Lewy body suggests that it may have a key role in the development of this aggregate. Similar results have been recently described by Spillantini et al, 20 using antibodies directed towards different regions of the alpha synuclein protein. This finding of alpha synuclein in the LB of sporadic PD cases suggests that the importance of alpha synuclein may extend well beyond a few cases of FPD, and indeed represent a common pathway, as a primary or secondary factor in the pathophysiology of Parkinson's disease in general. These results are consistent with our hypothesis that the missense Ala53Thr mutation seen in FPD cases leads to an abnormal conformation of the protein which is prone to self aggregation and which may promote the development of the structure described as LB. Our previous genotyping data of 52 sporadic cases of PD suggest that the Ala53Thr mutation is unlikely to be the cause of sporadic PD 2, but it is possible that other factors could cause a change in the conformation of otherwise normal alpha synuclein molecules, leading to the development of LB. Changes in the conformation of proteins could theoretically be promoted by a number of agents including other abnormally shaped proteins (as in the prion diseases), free radicals, oxidation, reduction, or extremes of temperature. 21 In addition, one can imagine genetic alterations that might contribute to the development of PD, including possible alterations in proteins commonly found in LB, such as the NF-H, L, and M proteins, 15 and genes responsible for the oxidative state of a cell, such as the superoxide dismutases. It is conceivable that a combination of these factors may be responsible for initiating the growth of the Lewy bodies and thereby causing the neuronal cell damage that eventually leads to the symptoms of PD. The observation of a plethora of fragmented cells and processes containing alpha synuclein in the diseased substantia nigra raises the question of their eventual fate. It is possible that the alpha synuclein aggregates may be taken up by other cells-after sick cells and their neurites break down-seeding the disease. This process of seeding has already been shown to operate in prion diseases and the [PSI+] phenotype in the yeast.
22,23
The mechanism we have proposed above may be a rather general one. Different clinical syndromes may be caused by the abnormal conformation of certain proteins whose patterns of expression and the insults to which they are exposed will determine the features of the disorder.
